



**SUPPLEMENTARY FIG. S4.** IC50 values were calculated for dose dependent effects of LNA ASOs tested in Fig. 2. *In vitro* transcription/translation assays with rabbit reticulocyte lysate were performed at varying LNA ASO concentrations and fixed Ebola luciferase reporter concentrations. Ebola luciferase reporter expression was measured and analyzed for each LNA ASO tested. All points are in reference to no treatment (set at 100%). For some points, the error bars would be shorter than the height of the *symbol*. In these cases, the error bars are not shown/visible. **(a)** % Inhibition of Ebola NP-luciferase fusion protein *in vitro* by LNA28 ASO is plotted based on dose-dependent titration assay. IC50 of LNA28 in this assay was calculated to be 1.145E-006M. **(b)** % Inhibition of Ebola NP-luciferase fusion protein *in vitro* by LNA29 ASO is plotted based on dose-dependent titration assay. IC50 of LNA29 in this assay was calculated to be 5.267E-006M. **(c)** % Inhibition of Ebola VP35-luciferase fusion protein *in vitro* by LNA30 ASO is plotted based on dose-dependent titration assay. IC50 of LNA30 in this assay was calculated to be 2.131E-006M. **(d)** % Inhibition of Ebola VP35-luciferase fusion protein *in vitro* by LNA31 ASO is plotted based on dose-dependent titration assay. IC50 of LNA31 in this assay was calculated to be 8.613E-007M. NP, nucleoprotein.